Ajax loader
By using our website, you agree to our use of cookies as described in Cookie Policy.

Can't find what you're looking for?

 

Be sure to Sign in to see all available content.

 

If you don't have an account, Register here.

Search results for: Experimental-medicine

GLOBAL-PHARMACEUTICAL/
RTS1UINL
June 30, 2018
Used blister packets that contained medicines, tablets and pills are seen, in this picture illustration...
London, United Kingdom
Used blister packets that contained medicines, tablets and pills are seen, in this picture illustration...
Used blister packets that contained medicines, tablets and pills are seen, in this picture illustration taken June 30, 2018. REUTERS/Russell Boyce/Illustration
GLOBAL-PHARMACEUTICAL/
RTS1UINK
June 30, 2018
Used blister packets that contained medicines, tablets and pills are seen, in this picture illustration...
London, United Kingdom
Used blister packets that contained medicines, tablets and pills are seen, in this picture illustration...
Used blister packets that contained medicines, tablets and pills are seen, in this picture illustration taken June 30, 2018. REUTERS/Russell Boyce/Illustration
GLOBAL-PHARMACEUTICAL/
RTS1UINJ
June 30, 2018
Used blister packets that contained medicines, tablets and pills are seen, in this picture illustration...
London, United Kingdom
Used blister packets that contained medicines, tablets and pills are seen, in this picture illustration...
Used blister packets that contained medicines, tablets and pills are seen, in this picture illustration taken June 30, 2018. REUTERS/Russell Boyce/Illustration
HEALTH-ZIKA/BRAZIL
RTX26K5K
February 11, 2016
A biologist displays frozen cells in the laboratory of Biology from University of Campinas (UNICAMP),...
Campinas, Brazil
A biologist displays frozen cells in the laboratory of Biology from University of Campinas in Campinas,...
A biologist displays frozen cells in the laboratory of Biology from University of Campinas (UNICAMP), in Campinas, Brazil, February 11, 2016. REUTERS/Paulo Whitaker
HEALTH-ZIKA/BRAZIL
RTX26K4I
February 11, 2016
A biologist works with Aedes mosquito cells in the laboratory of Biology from University of Campinas...
Campinas, Brazil
A biologist works with Aedes mosquito cells in the laboratory of Biology from University of Campinas...
A biologist works with Aedes mosquito cells in the laboratory of Biology from University of Campinas (UNICAMP), in Campinas, Brazil, February 11, 2016. According to UNICAMP, its scientists are developing a test to detect and identify the presence of genetic material associated with the Zika virus, dengue and Chikungunya in samples saliva, blood or urine. REUTERS/Paulo Whitaker
HEALTH-ZIKA/BRAZIL
RTX26K4H
February 11, 2016
A biologist displays Aedes mosquito cells inoculated with virus Zika in the laboratory of Biology from...
Campinas, Brazil
A biologist displays Aedes mosquito cells inoculated with virus Zika in the laboratory of Biology from...
A biologist displays Aedes mosquito cells inoculated with virus Zika in the laboratory of Biology from University of Campinas (UNICAMP), in Campinas, Brazil, February 11, 2016. According to UNICAMP, its scientists are developing a test to detect and identify the presence of genetic material associated with the Zika virus, dengue and Chikungunya in samples saliva, blood or urine. REUTERS/Paulo Whitaker
HEALTH-ZIKA/BRAZIL
RTX26K4E
February 11, 2016
A biologist displays Aedes mosquito cells inoculated with Zika virus in the laboratory of Biology from...
Campinas, Brazil
A biologist displays Aedes mosquito cells inoculated with Zika virus in the laboratory of Biology from...
A biologist displays Aedes mosquito cells inoculated with Zika virus in the laboratory of Biology from University of Campinas (UNICAMP), in Campinas, Brazil, February 11, 2016. According to UNICAMP, its scientists are developing a test to detect and identify the presence of genetic material associated with the Zika virus, dengue and Chikungunya in samples saliva, blood or urine. REUTERS/Paulo Whitaker
HEALTH-ZIKA/BRAZIL
RTX26K4D
February 11, 2016
A biologist works in the laboratory of Biology from University of Campinas (UNICAMP), in Campinas, Brazil,...
Campinas, Brazil
A biologist works in the laboratory of Biology from University of Campinas in Campinas, Brazil
A biologist works in the laboratory of Biology from University of Campinas (UNICAMP), in Campinas, Brazil, February 11, 2016. According to UNICAMP, its scientists are developing a test to detect and identify the presence of genetic material associated with the Zika virus, dengue and Chikungunya in samples saliva, blood or urine. REUTERS/Paulo Whitaker
HEALTH-ZIKA/BRAZIL
RTX26K4B
February 11, 2016
Aedes mosquito cells inoculated with Zika virus are seen through a microscope in the laboratory of Biology...
Campinas, Brazil
Aedes mosquito cells inoculated with Zika virus are seen through a microscope in the laboratory of Biology...
Aedes mosquito cells inoculated with Zika virus are seen through a microscope in the laboratory of Biology from University of Campinas (UNICAMP), in Campinas, Brazil, February 11, 2016. According to UNICAMP, its scientists are developing a test to detect and identify the presence of genetic material associated with the Zika virus, dengue and Chikungunya in samples saliva, blood or urine. REUTERS/Paulo Whitaker
HEALTH-ZIKA/BRAZIL
RTX26K4A
February 11, 2016
A biologist displays Aedes mosquito cells in the laboratory of Biology from University of Campinas (UNICAMP),...
Campinas, Brazil
A biologist displays Aedes mosquito cells in the laboratory of Biology from University of Campinas in...
A biologist displays Aedes mosquito cells in the laboratory of Biology from University of Campinas (UNICAMP), in Campinas, Brazil, February 11, 2016. According to UNICAMP, its scientists are developing a test to detect and identify the presence of genetic material associated with the Zika virus, dengue and Chikungunya in samples saliva, blood or urine. REUTERS/Paulo Whitaker
HEALTH-ZIKA/BRAZIL
RTX26K48
February 11, 2016
A biologist works with cell of Aedes mosquito in the laboratory of Biology from University of Campinas...
Campinas, Brazil
A biologist works with cell of Aedes mosquito in the laboratory of Biology from University of Campinas...
A biologist works with cell of Aedes mosquito in the laboratory of Biology from University of Campinas (UNICAMP), in Campinas, Brazil, February 11, 2016. According to UNICAMP, its scientists are developing a test to detect and identify the presence of genetic material associated with the Zika virus, dengue and Chikungunya in samples saliva, blood or urine. REUTERS/Paulo Whitaker
HEALTH-ZIKA/BRAZIL
RTX26K47
February 11, 2016
A biologist displays Aedes mosquito cells in the laboratory of Biology from University of Campinas (UNICAMP),...
Campinas, Brazil
A biologist displays Aedes mosquito cells in the laboratory of Biology from University of Campinas (UNICAMP),...
A biologist displays Aedes mosquito cells in the laboratory of Biology from University of Campinas (UNICAMP), in Campinas, Brazil, February 11, 2016. According to UNICAMP, its scientists are developing a test to detect and identify the presence of genetic material associated with the Zika virus, dengue and Chikungunya in samples saliva, blood or urine. REUTERS/Paulo Whitaker
FRANCE HEALTH/TEST
RTX22KJS
January 15, 2016
A logo is seen on a glass sign in front of the entrance of the Biotrial laboratory building in Rennes,...
Rennes, France
A logo is seen on a sign in front of the entrance of the Biotrial laboratory building in Rennes
A logo is seen on a glass sign in front of the entrance of the Biotrial laboratory building in Rennes, France, January 15, 2016. Portugal-based Bial lab is the manufacturer of the experimental medicine that sent six male volunteers in a trial of the drug to hospital in France, French Health Minister Marisol Touraine said on Friday. Touraine said the drug, which was being tested in a Phase I trial in France by Biotrial for Bial, contained neither cannabis nor any substance derived from cannabis. REUTERS/Stephane Mahe
FRANCE HEALTH/TEST
RTX22KJ7
January 15, 2016
A logo is seen on a glass sign in front of the entrance of the Biotrial laboratory building in Rennes,...
Rennes, France
A logo is seen on a sign in front of the entrance of the Biotrial laboratory building in Rennes
A logo is seen on a glass sign in front of the entrance of the Biotrial laboratory building in Rennes, France, January 15, 2016. Portugal-based Bial lab is the manufacturer of the experimental medicine that sent six male volunteers in a trial of the drug to hospital in France, French Health Minister Marisol Touraine said on Friday. Touraine said the drug, which was being tested in a Phase I trial in France by Biotrial for Bial, contained neither cannabis nor any substance derived from cannabis. REUTERS/Stephane Mahe
FRANCE HEALTH/TEST
RTX22KJ4
January 15, 2016
A logo is seen on a glass sign in front of the entrance of the Biotrial laboratory building in Rennes,...
Rennes, France
A logo is seen on a sign in front of the entrance of the Biotrial laboratory building in Rennes
A logo is seen on a glass sign in front of the entrance of the Biotrial laboratory building in Rennes, France, January 15, 2016. Portugal-based Bial lab is the manufacturer of the experimental medicine that sent six male volunteers in a trial of the drug to hospital in France, French Health Minister Marisol Touraine said on Friday. Touraine said the drug, which was being tested in a Phase I trial in France by Biotrial for Bial, contained neither cannabis nor any substance derived from cannabis. REUTERS/Stephane Mahe
FRANCE HEALTH/TEST
RTX22KJ2
January 15, 2016
A logo is seen on a glass sign in front of the entrance of the Biotrial laboratory building in Rennes,...
Rennes, France
A logo is seen on a sign in front of the entrance of the Biotrial laboratory building in Rennes
A logo is seen on a glass sign in front of the entrance of the Biotrial laboratory building in Rennes, France, January 15, 2016. Portugal-based Bial lab is the manufacturer of the experimental medicine that sent six male volunteers in a trial of the drug to hospital in France, French Health Minister Marisol Touraine said on Friday. Touraine said the drug, which was being tested in a Phase I trial in France by Biotrial for Bial, contained neither cannabis nor any substance derived from cannabis. REUTERS/Stephane Mahe
FRANCE HEALTH/TEST
RTX22KFX
January 15, 2016
A logo is seen on the facade of the Biotrial laboratory building in Rennes, France, January 15, 2016....
Rennes, France
A logo is seen on the facade of the Biotrial laboratory building in Rennes
A logo is seen on the facade of the Biotrial laboratory building in Rennes, France, January 15, 2016. Portugal-based Bial lab is the manufacturer of the experimental medicine that sent six male volunteers in a trial of the drug to hospital in France, French Health Minister Marisol Touraine said on Friday. Touraine said the drug, which was being tested in a Phase I trial in France by Biotrial for Bial, contained neither cannabis nor any substance derived from cannabis. REUTERS/Stephane Mahe
FRANCE HEALTH/TEST
RTX22KFM
January 15, 2016
A man walks past the Biotrial laboratory building in Rennes, France, January 15, 2016. Portugal-based...
Rennes, France
A man walks past the Biotrial laboratory building in Rennes
A man walks past the Biotrial laboratory building in Rennes, France, January 15, 2016. Portugal-based Bial lab is the manufacturer of the experimental medicine that sent six male volunteers in a trial of the drug to hospital in France, French Health Minister Marisol Touraine said on Friday. Touraine said the drug, which was being tested in a Phase I trial in France by Biotrial for Bial, contained neither cannabis nor any substance derived from cannabis. REUTERS/Stephane Mahe
FRANCE HEALTH/TEST
RTX22KF5
January 15, 2016
A man enters the Biotrial laboratory building in Rennes, France, January 15, 2016. Portugal-based Bial...
Rennes, France
A man enters the Biotrial laboratory building in Rennes
A man enters the Biotrial laboratory building in Rennes, France, January 15, 2016. Portugal-based Bial lab is the manufacturer of the experimental medicine that sent six male volunteers in a trial of the drug to hospital in France, French Health Minister Marisol Touraine said on Friday. Touraine said the drug, which was being tested in a Phase I trial in France by Biotrial for Bial, contained neither cannabis nor any substance derived from cannabis. REUTERS/Stephane Mahe
FRANCE HEALTH/TEST
RTX22KDA
January 15, 2016
A man enters the Biotrial laboratory building in Rennes, France, January 15, 2016. Portugal-based Bial...
Rennes, France
A man enters the Biotrial laboratory building in Rennes
A man enters the Biotrial laboratory building in Rennes, France, January 15, 2016. Portugal-based Bial lab is the manufacturer of the experimental medicine that sent six male volunteers in a trial of the drug to hospital in France, French Health Minister Marisol Touraine said on Friday. Touraine said the drug, which was being tested in a Phase I trial in France by Biotrial for Bial, contained neither cannabis nor any substance derived from cannabis. REUTERS/Stephane Mahe
FRANCE HEALTH/TEST
RTX22KB7
January 15, 2016
A logo is seen on a sign in front of the entrance of the Biotrial laboratory building in Rennes, France,...
Rennes, France
A logo is seen on a sign in front of the entrance of the Biotrial laboratory building in Rennes
A logo is seen on a sign in front of the entrance of the Biotrial laboratory building in Rennes, France, January 15, 2016. Portugal-based Bial lab is the manufacturer of the experimental medicine that sent six male volunteers in a trial of the drug to hospital in France, French Health Minister Marisol Touraine said on Friday. Touraine said the drug, which was being tested in a Phase I trial in France by Biotrial for Bial, contained neither cannabis nor any substance derived from cannabis. REUTERS/Stephane Mahe
FRANCE HEALTH/TEST
RTX22KB5
January 15, 2016
A sign is seen on a door at the entrance of the Biotrial laboratory building in Rennes, France, January...
Rennes, France
A sign is seen on a door at the entrance of the Biotrial laboratory building in Rennes
A sign is seen on a door at the entrance of the Biotrial laboratory building in Rennes, France, January 15, 2016. Portugal-based Bial lab is the manufacturer of the experimental medicine that sent six male volunteers in a trial of the drug to hospital in France, French Health Minister Marisol Touraine said on Friday. Touraine said the drug, which was being tested in a Phase I trial in France by Biotrial for Bial, contained neither cannabis nor any substance derived from cannabis. REUTERS/Stephane Mahe
FRANCE HEALTH/TEST
RTX22KAP
January 15, 2016
A logo is seen on the facade of the Biotrial laboratory building in Rennes, France, January 15, 2016....
Rennes, France
A logo is seen on the facade of the Biotrial laboratory building in Rennes
A logo is seen on the facade of the Biotrial laboratory building in Rennes, France, January 15, 2016. Portugal-based Bial lab is the manufacturer of the experimental medicine that sent six male volunteers in a trial of the drug to hospital in France, French Health Minister Marisol Touraine said on Friday. Touraine said the drug, which was being tested in a Phase I trial in France by Biotrial for Bial, contained neither cannabis nor any substance derived from cannabis. REUTERS/Stephane Mahe
FRANCE HEALTH/TEST
RTX22K99
January 15, 2016
A man enters the Biotrial laboratory building in Rennes, France, January 14, 2016. Portugal-based Bial...
Rennes, France
A man enters the Biotrial laboratory building in Rennes
A man enters the Biotrial laboratory building in Rennes, France, January 14, 2016. Portugal-based Bial lab is the manufacturer of the experimental medicine that sent six male volunteers in a trial of the drug to hospital in France, French Health Minister Marisol Touraine said on Friday. Touraine said the drug, which was being tested in a Phase I trial in France by Biotrial for Bial, contained neither cannabis nor any substance derived from cannabis. REUTERS/Stephane Mahe
FRANCE-HEALTH/TEST
RTX22K50
January 15, 2016
French Health Minister Marisol Touraine (R) and Gilles Hedan (L), professor of clinical neurology, leave...
Rennes, France
French Health Minister Marisol Touraine and Gilles Hedan, professor of clinical neurology, attend a news...
French Health Minister Marisol Touraine (R) and Gilles Hedan (L), professor of clinical neurology, leave after a news conference in Rennes, France, January 15, 2016. One person has been left brain dead and five others are in a serious condition after taking part in a clinical trial in France of an experimental medicine from an unnamed drug company, the French Health Ministry said on Friday. REUTERS/Stephane Mahe TPX IMAGES OF THE DAY
FRANCE-HEALTH/TEST
RTX22K13
January 15, 2016
French Health Minister Marisol Touraine and Gilles Hedan, professor of clinical neurology, attend a news...
Rennes, France
French Health Minister Marisol Touraine and Gilles Hedan, professor of clinical neurology, attend a news...
French Health Minister Marisol Touraine and Gilles Hedan, professor of clinical neurology, attend a news conference in Rennes, France, January 15, 2016. One person has been left brain dead and five others are in a serious condition after taking part in a clinical trial in France of an experimental medicine from an unnamed drug company, the French Health Ministry said on Friday. REUTERS/Stephane Mahe
FRANCE-HEALTH/TEST
RTX22K0Z
January 15, 2016
French Health Minister Marisol Touraine and Gilles Hedan, professor of clinical neurology, attend a news...
Rennes, France
French Health Minister Marisol Touraine and Gilles Hedan, professor of clinical neurology, attend a news...
French Health Minister Marisol Touraine and Gilles Hedan, professor of clinical neurology, attend a news conference in Rennes, France, January 15, 2016. One person has been left brain dead and five others are in a serious condition after taking part in a clinical trial in France of an experimental medicine from an unnamed drug company, the French Health Ministry said on Friday. REUTERS/Stephane Mahe
FRANCE-HEALTH/TEST
RTX22JYF
January 15, 2016
French Health Minister Marisol Touraine (L) arrives to attend a news conference in Rennes, France, January...
Rennes, France
French Health Minister Marisol Touraine arrives to attend a news conference in Rennes
French Health Minister Marisol Touraine (L) arrives to attend a news conference in Rennes, France, January 15, 2016. One person has been left brain dead and five others are in a serious condition after taking part in a clinical trial in France of an experimental medicine from an unnamed drug company, the French Health Ministry said on Friday. REUTERS/Stephane Mahe
FRANCE-HEALTH/TEST
RTX22JYE
January 15, 2016
French Health Minister Marisol Touraine arrives to attend a news conference in Rennes, France, January...
Rennes, France
French Health Minister Marisol Touraine arrives to attend a news conference in Rennes
French Health Minister Marisol Touraine arrives to attend a news conference in Rennes, France, January 15, 2016. One person has been left brain dead and five others are in a serious condition after taking part in a clinical trial in France of an experimental medicine from an unnamed drug company, the French Health Ministry said on Friday. REUTERS/Stephane Mahe
FRANCE-HEALTH/TEST
RTX22JY1
January 15, 2016
French Health Minister Marisol Touraine arrives to attend a news conference in Rennes, France, January...
Rennes, France
French Health Minister Marisol Touraine arrives to attend a news conference in Rennes
French Health Minister Marisol Touraine arrives to attend a news conference in Rennes, France, January 15, 2016. One person has been left brain dead and five others are in a serious condition after taking part in a clinical trial in France of an experimental medicine from an unnamed drug company, the French Health Ministry said on Friday. REUTERS/Stephane Mahe
TECH-CES/
RTX211IY
January 05, 2016
Jonathan Graff, director of clinical research for Apira Science demonstrates the company's iDerma Facial...
Las Vegas, UNITED STATES
Jonathan Graff, director of clinical research for Apira Science demonstrates the company's iDerma Facial...
Jonathan Graff, director of clinical research for Apira Science demonstrates the company's iDerma Facial Beautification System, that is designed to treat various skin-related disorders, at the Consumer Electronics Show in Las Vegas January 4, 2016. REUTERS/Rick Wilking
TECH-CES/
RTX211IJ
January 05, 2016
Jonathan Graff, director of clinical research for Apira Science demonstrates the company's iDerma Facial...
Las Vegas, UNITED STATES
Jonathan Graff, director of clinical research for Apira Science demonstrates the company's iDerma Facial...
Jonathan Graff, director of clinical research for Apira Science demonstrates the company's iDerma Facial Beautification System, that is designed to treat various skin-related disorders, at the Consumer Electronics Show in Las Vegas January 4, 2016. REUTERS/Rick Wilking
USA-ELECTION/BIDEN
RTX1QT00
September 02, 2015
U.S. Vice President Joe Biden comments while touring a biomedical lab in the Science Center at Miami...
Miami, UNITED STATES
U.S. Vice President Biden comments while touring biomedical lab at Miami Dade College North Campus in...
U.S. Vice President Joe Biden comments while touring a biomedical lab in the Science Center at Miami Dade College North Campus in Miami, Florida September 2, 2015. REUTERS/Joe Skipper TPX IMAGES OF THE DAY
USA-ELECTION/BIDEN
RTX1QSZJ
September 02, 2015
U.S. Vice President Joe Biden comments while touring a biomedical lab in the Science Center at Miami...
Miami, UNITED STATES
U.S. Vice President Biden tours biomedical lab at Miami Dade College North Campus in Miami
U.S. Vice President Joe Biden comments while touring a biomedical lab in the Science Center at Miami Dade College North Campus in Miami, Florida September 2, 2015. REUTERS/Joe Skipper
USA-ELECTION/BIDEN
RTX1QSZ1
September 02, 2015
U.S. Vice President Joe Biden arrives to tour a biomedical lab in the Science Center at Miami Dade College...
Miami, UNITED STATES
U.S. Vice President Biden arrives to tour a biomedical lab at Miami Dade College North Campus in Miami...
U.S. Vice President Joe Biden arrives to tour a biomedical lab in the Science Center at Miami Dade College North Campus in Miami, Florida September 2, 2015. REUTERS/Joe Skipper
USA-ELECTION/BIDEN
RTX1QSYP
September 02, 2015
U.S. Vice President Joe Biden (R) tours a biomedical lab in the Science Center at Miami Dade College...
Miami, UNITED STATES
U.S. Vice President Biden tours biomedical lab at Miami Dade College North Campus in Miami
U.S. Vice President Joe Biden (R) tours a biomedical lab in the Science Center at Miami Dade College North Campus in Miami, Florida September 2, 2015. REUTERS/Joe Skipper
USA-ELECTION/BIDEN
RTX1QSY9
September 02, 2015
U.S. Vice President Joe Biden tours a biomedical lab in the Science Center at Miami Dade College North...
Miami, UNITED STATES
U.S. Vice President Biden tours biomedical lab at Miami Dade College North Campus in Miami
U.S. Vice President Joe Biden tours a biomedical lab in the Science Center at Miami Dade College North Campus in Miami, Florida September 2, 2015. REUTERS/Joe Skipper
USA-ELECTION/BIDEN
RTX1QSXQ
September 02, 2015
U.S. Vice President Joe Biden arrives to tour a biomedical lab in the Science Center at Miami Dade College...
Miami, UNITED STATES
U.S. Vice President Biden arrives to tour a biomedical lab at Miami Dade College North Campus in Miami...
U.S. Vice President Joe Biden arrives to tour a biomedical lab in the Science Center at Miami Dade College North Campus in Miami, Florida September 2, 2015. REUTERS/Joe Skipper
HEALTH-EBOLA/
RTR4M60H
January 20, 2015
A volunteer receives a trial Ebola vaccine at the Centre for Clinical Vaccinology and Tropical Medicine...
Oxford, United Kingdom
A volunteer receives a trial Ebola vaccine at the Centre for Clinical Vaccinology and Tropical Medicine...
A volunteer receives a trial Ebola vaccine at the Centre for Clinical Vaccinology and Tropical Medicine in Oxford, southern England January 16, 2015. Johnson & Johnson said that newly formed groups supporting work on its experimental Ebola vaccine would receive 100 million euros ($115 million) from Europe's Innovative Medicines Initiative to speed development. Photograph taken January 16, 2015. REUTERS/Eddie Keogh (BRITAIN - Tags: SCIENCE TECHNOLOGY HEALTH)
HEALTH-EBOLA/
RTR4M602
January 20, 2015
Volunteer Andrew Matzen receives a trial Ebola vaccine at the Centre for Clinical Vaccinology and Tropical...
Oxford, United Kingdom
Volunteer Andrew Matzen receives a trial Ebola vaccine at the Centre for Clinical Vaccinology and Tropical...
Volunteer Andrew Matzen receives a trial Ebola vaccine at the Centre for Clinical Vaccinology and Tropical Medicine in Oxford, southern England January 16, 2015. Johnson & Johnson said that newly formed groups supporting work on its experimental Ebola vaccine would receive 100 million euros ($115 million) from Europe's Innovative Medicines Initiative to speed development. Photograph taken January 16, 2015. REUTERS/Eddie Keogh (BRITAIN - Tags: SCIENCE TECHNOLOGY HEALTH)
HEALTH-EBOLA/
RTR4M5ZX
January 20, 2015
Volunteer Joshua Coombs receives a trial Ebola vaccine at the Centre for Clinical Vaccinology and Tropical...
Oxford, United Kingdom
Volunteer Joshua Coombs receives a trial Ebola vaccine at the Centre for Clinical Vaccinology and Tropical...
Volunteer Joshua Coombs receives a trial Ebola vaccine at the Centre for Clinical Vaccinology and Tropical Medicine in Oxford, southern England January 16, 2015. Johnson & Johnson said that newly formed groups supporting work on its experimental Ebola vaccine would receive 100 million euros ($115 million) from Europe's Innovative Medicines Initiative to speed development. Photograph taken January 16, 2015. REUTERS/Eddie Keogh (BRITAIN - Tags: SCIENCE TECHNOLOGY HEALTH)
HEALTH-EBOLA/USA
RTR4918O
October 05, 2014
A worker in a hazardous material suit looks on from a balcony as they remove the contents from the apartment...
Dallas, UNITED STATES
A worker in a hazardous material suit looks on from a balcony as they remove the contents from the apartment...
A worker in a hazardous material suit looks on from a balcony as they remove the contents from the apartment unit where a man diagnosed with the Ebola virus was staying in Dallas, Texas, October 5, 2014. Thomas Eric Duncan, the first person diagnosed with Ebola in the United States, was fighting for his life at a Dallas hospital on Sunday and appeared not to be receiving any of the experimental medicines for the virus, a top U.S. medical official said. REUTERS/Jim Young (UNITED STATES - Tags: HEALTH)
HEALTH-EBOLA/USA-CHURCH
RTR4918F
October 05, 2014
A parishioner takes part in a church service dedicated to the victims of the Ebola crisis at New Life...
EULESS, UNITED STATES
A parishioner takes part in a church service dedicated to the victims of the Ebola crisis at New Life...
A parishioner takes part in a church service dedicated to the victims of the Ebola crisis at New Life Fellowship Church in Euless, Texas, October 5, 2014. T Thomas Eric Duncan, the first person diagnosed with Ebola in the United States, was fighting for his life at a Dallas hospital on Sunday and appeared not to be receiving any of the experimental medicines for the virus, a top U.S. medical official said. REUTERS/Jim Young (UNITED STATES - Tags: HEALTH RELIGION)
HEALTH-EBOLA/USA
RTR4917R
October 05, 2014
A worker in a hazardous material suit looks on from a balcony as they remove the contents from the apartment...
Dallas, UNITED STATES
A worker in a hazardous material suit looks on from a balcony as they remove the contents from the apartment...
A worker in a hazardous material suit looks on from a balcony as they remove the contents from the apartment unit where a man diagnosed with the Ebola virus was staying in Dallas, Texas, October 5, 2014. Thomas Eric Duncan, the first person diagnosed with Ebola in the United States, was fighting for his life at a Dallas hospital on Sunday and appeared not to be receiving any of the experimental medicines for the virus, a top U.S. medical official said. REUTERS/Jim Young (UNITED STATES - Tags: HEALTH)
HEALTH-EBOLA/USA
RTR4917M
October 05, 2014
A worker in a hazardous material suit carries out a barrel of contents from the apartment unit where...
Dallas, UNITED STATES
A worker in a hazardous material suit carries out a barrel of contents from the apartment unit where...
A worker in a hazardous material suit carries out a barrel of contents from the apartment unit where a man diagnosed with the Ebola virus was staying in Dallas, Texas, October 5, 2014. Thomas Eric Duncan, the first person diagnosed with Ebola in the United States, was fighting for his life at a Dallas hospital on Sunday and appeared not to be receiving any of the experimental medicines for the virus, a top U.S. medical official said. REUTERS/Jim Young (UNITED STATES - Tags: HEALTH)
HEALTH-EBOLA/USA
RTR4917H
October 05, 2014
A worker in a hazardous material suit carries in a barrel to remove the contents from the apartment unit...
Dallas, UNITED STATES
A worker in a hazardous material suit carries in a barrel to remove the contents from the apartment unit...
A worker in a hazardous material suit carries in a barrel to remove the contents from the apartment unit where a man diagnosed with the Ebola virus was staying in Dallas, Texas, October 5, 2014. Thomas Eric Duncan, the first person diagnosed with Ebola in the United States, was fighting for his life at a Dallas hospital on Sunday and appeared not to be receiving any of the experimental medicines for the virus, a top U.S. medical official said. REUTERS/Jim Young (UNITED STATES - Tags: HEALTH)
HEALTH-EBOLA/USA
RTR49176
October 05, 2014
A worker in a hazardous material suit looks out from the apartment unit where a man diagnosed with the...
Dallas, UNITED STATES
A worker in a hazardous material suit looks out from the apartment unit where a man diagnosed with the...
A worker in a hazardous material suit looks out from the apartment unit where a man diagnosed with the Ebola virus was staying in Dallas, Texas, October 5, 2014. Thomas Eric Duncan, the first person diagnosed with Ebola in the United States, was fighting for his life at a Dallas hospital on Sunday and appeared not to be receiving any of the experimental medicines for the virus, a top U.S. medical official said. REUTERS/Jim Young (UNITED STATES - Tags: HEALTH)
HEALTH-EBOLA/USA
RTR4916Y
October 05, 2014
A worker in a hazardous material suit carries out a barrel of contents from the apartment unit where...
Dallas, UNITED STATES
A worker in a hazardous material suit carries out a barrel of contents from the apartment unit where...
A worker in a hazardous material suit carries out a barrel of contents from the apartment unit where a man diagnosed with the Ebola virus was staying in Dallas, Texas, October 5, 2014. Thomas Eric Duncan, the first person diagnosed with Ebola in the United States, was fighting for his life at a Dallas hospital on Sunday and appeared not to be receiving any of the experimental medicines for the virus, a top U.S. medical official said. REUTERS/Jim Young (UNITED STATES - Tags: HEALTH)
HEALTH-EBOLA/USA
RTR4916V
October 05, 2014
A worker in a hazardous material suit carries out a barrel of contents from the apartment unit where...
Dallas, UNITED STATES
A worker in a hazardous material suit carries out a barrel of contents from the apartment unit where...
A worker in a hazardous material suit carries out a barrel of contents from the apartment unit where a man diagnosed with the Ebola virus was staying as children watch from a neighboring apartment in Dallas, Texas, October 5, 2014. Thomas Eric Duncan, the first person diagnosed with Ebola in the United States, was fighting for his life at a Dallas hospital on Sunday and appeared not to be receiving any of the experimental medicines for the virus, a top U.S. medical official said. REUTERS/Jim Young (UNITED STATES - Tags: HEALTH)
HEALTH-EBOLA/USA
RTR4916S
October 05, 2014
A worker in a hazardous material suit seals up a barrel at the apartment unit where a man diagnosed with...
Dallas, UNITED STATES
A worker in a hazardous material suit seals up a barrel at the apartment unit where a man diagnosed with...
A worker in a hazardous material suit seals up a barrel at the apartment unit where a man diagnosed with the Ebola virus was staying in Dallas October 5, 2014. Thomas Eric Duncan, the first person diagnosed with Ebola in the United States, was fighting for his life at a Dallas hospital on Sunday and appeared not to be receiving any of the experimental medicines for the virus, a top U.S. medical official said. REUTERS/Jim Young (UNITED STATES - Tags: HEALTH)
HEALTH-EBOLA/USA
RTR49166
October 05, 2014
A worker in a hazardous material suit rolls out barrels of contents from the apartment unit where a man...
Dallas, UNITED STATES
A worker in a hazardous material suit rolls out barrels of contents from the apartment unit where a man...
A worker in a hazardous material suit rolls out barrels of contents from the apartment unit where a man diagnosed with the Ebola virus was staying in Dallas October 5, 2014. Thomas Eric Duncan, the first person diagnosed with Ebola in the United States, was fighting for his life at a Dallas hospital on Sunday and appeared not to be receiving any of the experimental medicines for the virus, a top U.S. medical official said. REUTERS/Jim Young (UNITED STATES - Tags: HEALTH)
HEALTH-EBOLA/VACCINE
RTR46MJN
September 17, 2014
Volunteer Ruth Atkins receives an injection of the Ebola vaccine, at the Oxford Vaccine Group Centre...
Oxford, United Kingdom
Volunteer Ruth Atkins receives an injection of the Ebola vaccine at the Oxford Vaccine Group Centre for...
Volunteer Ruth Atkins receives an injection of the Ebola vaccine, at the Oxford Vaccine Group Centre for Clinical Vaccinology and Tropical Medicine (CCVTM) in Oxford, southern England September 17, 2014. The first volunteer in a fast-tracked British safety trial of an experimental Ebola vaccine made by GlaxoSmithKline received the injection on Wednesday, trial organizers said. REUTERS/Steve Parsons/Pool (BRITAIN - Tags: HEALTH SCIENCE TECHNOLOGY)
HEALTH-EBOLA/VACCINE
RTR46MJ9
September 17, 2014
Volunteer Ruth Atkins receives an injection of the Ebola vaccine, at the Oxford Vaccine Group Centre...
Oxford, United Kingdom
Volunteer Ruth Atkins receives an injection of the ebola vaccine at the Oxford Vaccine Group Centre for...
Volunteer Ruth Atkins receives an injection of the Ebola vaccine, at the Oxford Vaccine Group Centre for Clinical Vaccinology and Tropical Medicine (CCVTM) in Oxford, southern England September 17, 2014. The first volunteer in a fast-tracked British safety trial of an experimental Ebola vaccine made by GlaxoSmithKline received the injection on Wednesday, trial organizers said. REUTERS/Steve Parsons/Pool (BRITAIN - Tags: HEALTH SCIENCE TECHNOLOGY)
HEALTH-EBOLA/VACCINE
RTR46MJ6
September 17, 2014
Professor Adrian Hill, Director of the Jenner Institute, and Chief Investigator of the trials, holds...
Oxford, United Kingdom
Professor Adrian Hill, Director of the Jenner Institute, and Chief Investigator of the trials, holds...
Professor Adrian Hill, Director of the Jenner Institute, and Chief Investigator of the trials, holds a phial containing the Ebola vaccine at the Oxford Vaccine Group Centre for Clinical Vaccinology and Tropical Medicine (CCVTM) in Oxford, southern England September 17, 2014. The first volunteer in a fast-tracked British safety trial of an experimental Ebola vaccine made by GlaxoSmithKline received the injection on Wednesday, trial organizers said. REUTERS/Steve Parsons/Pool (BRITAIN - Tags: HEALTH SCIENCE TECHNOLOGY)
HEALTH-EBOLA/VACCINE
RTR46MIR
September 17, 2014
Professor Adrian Hill, Director of the Jenner Institute, and Chief Investigator of the trials, holds...
Oxford, United Kingdom
Professor Adrian Hill, Director of the Jenner Institute, and Chief Investigator of the trials, holds...
Professor Adrian Hill, Director of the Jenner Institute, and Chief Investigator of the trials, holds a phial containing the Ebola vaccine at the Oxford Vaccine Group Centre for Clinical Vaccinology and Tropical Medicine (CCVTM) in Oxford, southern England September 17, 2014. The first volunteer in a fast-tracked British safety trial of an experimental Ebola vaccine made by GlaxoSmithKline received the injection on Wednesday, trial organizers said. REUTERS/Steve Parsons/Pool (BRITAIN - Tags: HEALTH SCIENCE TECHNOLOGY)
HEALTH-EBOLA/VACCINE
RTR46MIN
September 17, 2014
Professor Adrian Hill, Director of the Jenner Institute, and Chief Investigator of the trials, holds...
Oxford, United Kingdom
Professor Adrian Hill, Director of the Jenner Institute, and Chief Investigator of the trials, holds...
Professor Adrian Hill, Director of the Jenner Institute, and Chief Investigator of the trials, holds a phial containing the Ebola vaccine at the Oxford Vaccine Group Centre for Clinical Vaccinology and Tropical Medicine (CCVTM) in Oxford, southern England September 17, 2014. The first volunteer in a fast-tracked British safety trial of an experimental Ebola vaccine made by GlaxoSmithKline received the injection on Wednesday, trial organizers said. REUTERS/Steve Parsons/Pool (BRITAIN - Tags: HEALTH SCIENCE TECHNOLOGY TPX IMAGES OF THE DAY)
HEALTH-EBOLA/VACCINE
RTR46MHV
September 17, 2014
Volunteer Ruth Atkins has blood taken before receiving an injection of the Ebola vaccine at the Oxford...
Oxford, United Kingdom
Volunteer Ruth Atkins has blood taken before receiving an injection of the Ebola vaccine at the Oxford...
Volunteer Ruth Atkins has blood taken before receiving an injection of the Ebola vaccine at the Oxford Vaccine Group Centre for Clinical Vaccinology and Tropical Medicine (CCVTM) in Oxford, southern England September 17, 2014. The first volunteer in a fast-tracked British safety trial of an experimental Ebola vaccine made by GlaxoSmithKline received the injection on Wednesday, trial organizers said. REUTERS/Steve Parsons/Pool (BRITAIN - Tags: HEALTH SCIENCE TECHNOLOGY)
HEALTH-EBOLA/VACCINE
RTR46MHK
September 17, 2014
Volunteer Ruth Atkins poses for a photograph before receiving an injection of the Ebola vaccine, at the...
Oxford, United Kingdom
Volunteer Ruth Atkins poses for a photograph before receiving an injection of the Ebola vaccine, at the...
Volunteer Ruth Atkins poses for a photograph before receiving an injection of the Ebola vaccine, at the Oxford Vaccine Group Centre for Clinical Vaccinology and Tropical Medicine (CCVTM) in Oxford, southern England September 17, 2014. The first volunteer in a fast-tracked British safety trial of an experimental Ebola vaccine made by GlaxoSmithKline received the injection on Wednesday, trial organizers said. REUTERS/Steve Parsons/Pool (BRITAIN - Tags: HEALTH SCIENCE TECHNOLOGY)
GERMANY-SCIENCE/
RTR45SGY
September 11, 2014
Test person Niklas Thiel poses with an electroencephalography (EEG) cap which measures brain activity,...
Garching, Germany
Test person Thiel poses with an electroencephalography cap which measures brain activity, at the Technische...
Test person Niklas Thiel poses with an electroencephalography (EEG) cap which measures brain activity, at the Technische Universitaet Muenchen (TUM) in Garching near Munich September 9, 2014. The researchers from TUM and the Technische Universitaet Berlin (team Phypa) try to find ways to control an airplane with computer translated brain impulses without the pilot touching the plane's controls. The solution, if achieved, would contribute to greater flight safety and reduce pilots' workload. Picture taken September 9, 2014. REUTERS/Michaela Rehle (GERMANY - Tags: HEADSHOT SOCIETY SCIENCE TECHNOLOGY)
GERMANY-SCIENCE/
RTR45SGJ
September 11, 2014
A combination of four pictures shows test person Niklas Thiel posing with an electroencephalography (EEG)...
Garching, Germany
A combination of four pictures shows test person Thiel posing with an electroencephalography cap at the...
A combination of four pictures shows test person Niklas Thiel posing with an electroencephalography (EEG) cap which measures brain activity, at the Technische Universitaet Muenchen (TUM) in Garching near Munich September 9, 2014. The researchers from TUM and the Technische Universitaet Berlin (team Phypa) try to find ways to control an airplane with computer translated brain impulses without the pilot touching the plane's controls. The solution, if achieved, would contribute to greater flight safety and reduce pilots' workload. Picture taken September 9, 2014. REUTERS/Michaela Rehle (GERMANY - Tags: SCIENCE TECHNOLOGY SOCIETY TPX IMAGES OF THE DAY)
Sort by
Display
Items per page
Page
of 3